Section Review Central & Peripheral Nervous Systems: Novel anxiolytic agents - 1994 to present

References

• WALLEY EJ, BEEBE DK, CLARK JL: Management of common anxiety disorders. American Family Physician (1994) 1745–1753.
   Google Scholar
• WOODS JH, WINGER G: Current lbenzodiazepine issues. Psychopharmacology (1995) 118:107–115.
   PubMed Web of Science ®Google Scholar
• HANDLEY S: Future prospects for the pharmacological treatment of anxiety. CNS Drugs (1994) 2:397–414.
   Google Scholar
• WOODS JH, KATZ KL, WINGER G: Abuse and therapeutic use of benzodiazepines and benzodiazepine-like drugs. In: Psychopharmacology: The Fourth Generation of Progress. Bloom FE, Kupfer DJ, (Eds.), Raven Press, New York (1995):1777–1792.
   Google Scholar
• PRATT JA: The neuroanatomienl basis of anxiety. Phar-macol. Ther. (1992) 55:149–181.
   PubMed Web of Science ®Google Scholar
• DAWSON GR, TRICKLEBANK MD: Use of the elevated plus maze in the search for novel anxiolytic agents. Trends Pharmacol. Sci. (1995) 16:33–36.
   PubMed Web of Science ®Google Scholar
• TULINSICY J, GAMMILL RB: The chemistry and pharmacology of GABAA and GABAB ligands. Curr. Med. Chem. (1994) 3:226–253.
   Google Scholar
• SMITH GB, OLSEN RW: Functional domains of GABAA receptors. Trends Pharmacol. Sci. (1995) 16:162–168.
   PubMed Web of Science ®Google Scholar
• POTOKAR J, NUTT DJ: Anxiolytic potential of ben-zodiazepine receptor partial agonists. C1VS Drugs (1994) 1:305–315.
   Google Scholar
• LUDDENS H, PRITCHETT DB, KOHLER M et al.: Cerebellar GABAA receptor selective for a behavioural alcohol antagonist. Nature (1990) 346:648–651.
   PubMed Web of Science ®Google Scholar
• STEPHENSON FA: The GABAA receptors. Biochem.J. (1995) 310:1–9.
   PubMedGoogle Scholar
• PRITCHE'rT DB, SEEBURG PH: y-Aminobutyric add typeA receptor point mutation increases the affinity of compounds for the benzodiazepine site. Proc. Natl. Acad. Sci. USA (1991) 88:1421–1425.
   Google Scholar
• MIHIC SJ, WHITING PJ, KLEIN RL, WAFFORD KA, HARRISRA: A single amino add of the human y-aminobutyrk acid type A receptor y2 subunit determines ben-zodiazepine efficacy. J. Biol. Chem. (1994) 269:32768–32773.
   PubMed Web of Science ®Google Scholar
• YASUMATSU H, MORIMOTO Y, YAMAMOTO Y et al.: Thepharmacological properties of Y-23684, a ben-zodiazepine receptor partial agonist. Br. J. Pharmacol. (1994) 111:1170–1178.
   PubMedGoogle Scholar
• Drug News and Perspect. (1995) 8:242.
   Google Scholar
• TENBRINK RE, IM WB, SETHY VH, TANG AR, CARTER DB: Antagonist, partial agonist, and full agonist imidazo[1,5-a]quinoxaline amides and carbamates acting through the GABAA/benzodiazepine receptor. J. Med. Chem. (1994) 37:758–768.
   PubMed Web of Science ®Google Scholar
• MARYANOFF BE, HO W, MCCOMSEY DF et al.: Potentialanxiolytic agents. Pyridoi1,2-albenzimidazoles. J. Med. Chem. (1995) 38:16–20.
   Google Scholar
• MARYANOFF BE, MCCOMSEY DF, HO W, SHANK RP, DUBINSKY B: Potential anxiolytic agents. 2. Improve-ment of oral efficacy for the pyriclo[1,2-a]benzimida-zole (PHI) class of GABAA receptor modulators. BioMed. Chem. Lett. (1996) 6:333–338.
   Google Scholar
• VILLAR HO, UYENO ET, TOLL L et al.: Molecular determi-nants of benzodiazepine receptor affinities and anti-convulsant activities. Mol. Pharmacol. (1989) 36:589–600.
   PubMedGoogle Scholar
• COLOTTA V, CATARZI D, VARANO F et al.: Ben-zodiazepine binding activity of some tricycle het-eroaromatic systems to define the hydrogen binding strength of the proton donors of the receptor site. II Farmaco (1996) 51:223–229.
   Google Scholar
• LAMBERT JJ, BELELLI D, HILL-VENNING C, PETERS JA: Neurosteroids and GABAA receptor function. Trends Pharmacol. Sci. (1995) 16:295–303.
   PubMed Web of Science ®Google Scholar
• NGUYEN Q, SAPP DW, VAN NESS PC, OLSEN RW: Modu-lation of GABAA receptor binding in human brain by neuroactive steroids. Synapse (1995) 19:77–87.
   PubMedGoogle Scholar
• WOOD PL: Neuroactive steroids as anadolytics. IBC's International Symposium on Depression &Anxiety. Philadel-phia, PA (1995).
   Google Scholar
• HU Y, ZORUMSKI CF, COVEY DF: Neurosteroid ana-logues. 2. Total synthesis and eledrophysiological evaluation of benz[e]indene analogues of the anesthetic steroid alphaxalone. J. Otg. Chem. (1995) 60:3619–3625.
   Google Scholar
• HAN M, HU Y, ZORUMSKI CF, COVEY DF: Neurosteroid analogues. 3. The synthesis and electrophysiological evaluation of benz[e]lndene congeners of neuroactive steroids having the 513-configuration. J. Med. Chem. (1995) 38:4548–4556.
   Google Scholar
• WILKERSON LO, DOURISH CT: Serotonin and animal behaviour. In: Serotonin Receptor Subtypes: Basic and Clini-cal Aspects. Peroutka SJ (Ed.), Wiley-Liss, New York (1991):147–210.
   Google Scholar
• SLEIGHT AJ, PIERCE PA, SCHMIDT AW, HEKMATPANAH CR, PEROUTKA SJ: The clinical utility of serotordn recep-tor active agents in neuropsychiatry. In: Serotonin Re-ceptor Subtypes: Basic and Clinical Aspects. Peroutka SJ (Ed), Wiley-Liss, New York (1991):211–227.
   Google Scholar
• SANDOU F, HEN R: 5-Hydroxytryptamine receptor sub-types in vertebrates and invertebrates. Neurochem. Int. (1994) 25:503–532.
   PubMedGoogle Scholar
• SAXENA PR: Serotonin receptors: subtypes, functional responses and therapeutic relevance. Pharmacol. Ther. (1995) 66:339–368.
   PubMed Web of Science ®Google Scholar
• HAMON M: Neuropharmacology of anxiety: perspec-tives and prospects. Trends Pharmacol. Sci. (1994) 15:36–39.
   PubMedGoogle Scholar
• PECKNOLD JC: Serotonin 5-HT1A agonists: a comparative review. CNS Drugs (1994) 2:234–251.
   Google Scholar
• DE MONTIGNY C, BLIER P: Electrophysical properties of 5-HT1A receptors and of 5-11T1A agonists. In: Serotonin-1A Receptors in Depression and Anxiety. Stahl S, Gastpar M, Keppel M, Hesselink JM (Eds.), Raven Press, New York (1994:83–98.
   Google Scholar
• COSTALL B, DOMENY AM, FARRE AJ et at: Profile of actionof a novel 5-hydroxytryptamine-1A receptor ligand E-4424 to inhibit aversive behavior in the mouse, rat, and marmoset. J. Pharmacol. Exp. Ther. (1992) 262:90–98.
   PubMed Web of Science ®Google Scholar
• FLETCHER A, CLIFFE IA, DOURISH CT: Silent 5-11T1A receptor antagonists: utility as research tools and thera-peutic agents. Trends Pharmacol. Sci. (1993) 14:441–448.
   Web of Science ®Google Scholar
• FLETCHER A, BILL DJ, BILL SJ et al.: WAY100135: a novel, selective antagonist at presynaptic and postsynaptic 5-11T1A receptors. Eur. J. Pharmacol. (1993) 237:283–291.
   PubMed Web of Science ®Google Scholar
• WAEBER C, SCHOEFFER P, HOVER D, PALACIOS JM: The serotonin 5-11Tio receptor: a progress review. Neuro-chem. Res. (1990) 15:573–588.
   Google Scholar
• SKINGLE M, SCOPES DIC, FENIUK W et al.: GR127935: apotent orally active 5-11Tio receptor antagonist. Brit. J. Pharmacol. (1993) 110:9P.
   Web of Science ®Google Scholar
• CLITHEROW JW, SCOPES DI, SKINGLE M et al.: Evolution of a novel series of KN,N-dimethylamino)propyl]- and piperazinylbenzanilides as the first selective 5-11Tio antagonists. J. Med. Chem. (1994) 37:2253–2257.
   PubMed Web of Science ®Google Scholar
• BLACKBURN TP: 5-LIT receptors and anxiolytics drugs. In: Central Serotonin Receptors and Psychotropic Drugs. Marsden CA, Heal DJ (Eds.), Blackwell Scientific Publications, London (1992):175–197.
   Google Scholar
• NUTT DJ: The pharmacology of human anxiety. Phar-macol. Ther. (1990) 47:233–266.
   PubMedGoogle Scholar
• NUTT DJ, LAWSON L: Panic attacks: an overview of models and mechanisms. Br.J. Psych. (1992) 160:165–178.
   PubMed Web of Science ®Google Scholar
• COPLAN JD, GORMAN JM, KLEIN DF: Serotonin related functions in panic-anxiety: a critical overview. Neurop-sychopharmacology (1992) 6:189–200.
   PubMed Web of Science ®Google Scholar
• FULLER RW: Clinical applications of 5-LIT uptake inhibi-tors. Adv Bio.Sci. (1992) 85:255–296.
   Google Scholar
• MONTGOMERY SA, MANCEAUX A: Fluvoxamine in the treatment of obsessive compulsive disorder. Int. Clin. Psychopbarmacol. (1992) 7\(Suppl. 1): 5–9.
   Google Scholar
• GOODMAN WK, MCDOUGLE CJ, BARR LC, ARONSON SC, PRICE LH: Biological approaches to treatment-resistant obsessive compulsive disorder. J. Clin. Psych. (1993) 54:16–26.
   Google Scholar
• MORAN TH, ROBINSON PH, GOLDRECK MS, MCHUGH PR: Two brain cholecystokinin receptors: implications for behavioral actions. Brain Res. (1986) 362:175–179.
   PubMed Web of Science ®Google Scholar
• HILL DR, SINGH L, BODEN P et al.: Detection of CCK receptor subtypes in mammalian brains using highly selective non-peptide agonists. In: Multiple Chokcystok-inin Receptors in the CNS. Cooper ST, Dourish CD, Iversen SD (Eds.), Oxford University Press, Oxford (1992):57–76.
   Google Scholar
• LYD1ARD RB: Neuropeptides and anxiety: focus on cholecystokinin. Clin. Chem. (1994) 40:315–318.
   PubMedGoogle Scholar
• WOODRUFF GN, HUGHES J: Cholecystokinin antago-nists. Ann. Rev. Pharmacol. Taxicol. (1991) 31:469–501.
   PubMed Web of Science ®Google Scholar
• DUBOVS1CY S: Approaches to developing new anx-iolytics and antidepressants. J. Clin. Psychiatry (1993) 54:75–83.
   PubMedGoogle Scholar
• WROBLESKI JT, DANYSZ W: Modulation of glutamatereceptors: molecular mechanism and functional impli-cations. Ann. Rev. Pharmacol. Toxicol. (1989) 29:441–474.
   PubMedGoogle Scholar
• MCBAIN CJ, MAYER ML: N-methyl-D-aspartie add recep-tor structure and function. Physiol. Rev. (1994)74:723–760.
   PubMed Web of Science ®Google Scholar
• BENNETT DA, AMRICK Cl: Antagonists at the NMDA receptor produces anticonflict effects. EAAT (1987) 1:213–216.
   Google Scholar
• CLINESCHMIDT By, WILLIAMS M, WITOSLAVSKI JJ et al.:Restoration of shock-suppressed behavior by treatment with (+)-5-methy1-10,11-dihydro-5H-dibenzo[a,d]cycko-hepten-5,10-imine, a substance with potent anticonvul-sant, central sympatominaetic, and apparent anxiolytic properties. Drug Dev. Res. (1982) 2:147–163.
   Google Scholar
• ADAMEC RE, SAYIN U, BROWN A: The effects of corticot-rophin releasing factor (CRF) and handling stress on behavior in the elevated plus-maze test of anxiety. J. Psychopharmacol (1991) 5:175–186.
   PubMedGoogle Scholar
• SAWCHENKO PE, IMAKI T, POTTER E: The functional neuroanatomy of corticotrophin-releasing factor. In: Corticotrophin-Releasing Factor. Corti RF, Chadwick DJ, Marsh J (Eds.), Wiley, Chichester (1993) 172:5–29.
   Google Scholar
• DUNN AJ, BERRIDGE CW: Physiological and behavioralresponses to corticotropin-releasing factor administra-tion: is CRF a mediator of anxiety or stress responses? Brain Res. Rev. (1990) 15:71–100.
   Google Scholar
• KOOB GF, HEINRICHS SC, PICH EM: The role of cortioot-ropin-releasing factor in behavioral responses to stress. In: Corticotrophin-Releasing Factor. Corti RF, Chadwick DJ, Marsh J (Eds.), Wiley, Chichester (1993) 172:277–295.
   Google Scholar
• WAHLESTEDT C, REIS DJ: Neuropeptide Y-related pep-tides and their receptors: are the receptors potential therapeutic drug targets? Ann. Rev. Pharmacol. Toxicol. (1993) 32:309-352. Excellent review article on neuropeptide Y.
   Google Scholar
• COLMERS WF, BLEAKMAN D: Effects of neuropeptide Yon the electrical properties of neurons. Trends Neurol. Sci. (1994) 14:373–379.
   Google Scholar
• WAHLESTEDT C, PICH EM, KOOB GF, YEE F, HEILIG M:Modulation of anxiety and neuropeptide Y - Yi recep-tors by antisense oligodeoxynucleotides. Science (1993) 259:528–531.
   PubMed Web of Science ®Google Scholar
• GEHLERT DR: Subtypes of receptors for neuropeptide Y:Implications for the targeting of therapeutics. Life Sci. (1994) 55:551–562.
   PubMed Web of Science ®Google Scholar
• WAN CP, LAU BHS: Neuropeptide Y receptor subtypes.Life Sci. (1995) 56:1055–1064.
   PubMedGoogle Scholar
• GERARD C, WALKER MW, BARD JA et al.: Expression,cloning, and pharmacological characterization of a human hippocampal neuropeptide Y/peptide YY re-ceptor subtype. Meeting of the Society of Neuroscience. San Diego, CA (1995) Abstract 402.3.
   Google Scholar
• BARD JA, WALKER MW, BRANCHEK TA, WEINSHANK RL:Cloning and characterization of the novel human neuropeptide Y/peptide YY pancreatic receptor system (Y-4). Meeting of the Society of Neuroscience. San Diego, CA (1995) Abstract 402.4.
   Google Scholar
• GERALD C, WALKER MW, CRISCIONE L et al.: A receptorsubtype involved in neuropeptide-Y-induced food in-take. Nature (1996) 382:168–171.
   PubMed Web of Science ®Google Scholar
• PRIVETTE TH, TERRIAN DM: Kappa opioid agonists pro-duce anxiolytic-like behaviour on the elevated-plus maze. Psychopharmacology. (1995) 118:444–450.
   PubMed Web of Science ®Google Scholar